You are here: Home Our Members Principal Investigators
Ingo Hilgendorf Profile Page
Ingo Hilgendorf


Lab: Dr. Ingo Hilgendorf
Department: Emmy Noether Group Leader
Heart Center Freiburg, University of Freiburg
Department of Cardiology and Angiology I
Address: Hugstetterstr. 55
79106 Freiburg
Phone: +49 761 270-34010 (hospital), -70081 (lab), Fax: -70089
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Lab homepage:
PhD positions available: YES
Research Area: Molecular Medicine
Research Interests: - Identification of inflammatory processes responsible for the imbalanced immune response in atherosclerosis, myocardial infarction and other cardiovascular diseases
- Defining feasible targets for immunomodulation to restore proper resolution of inflammation


Education & Training: 05/2008: Medical doctoral degree from the Medical Faculty, Eberhard Karls University Tuebingen
10/2000 - 06/2007: Medical studies at Eberhard Karls University Tuebingen, Germany
and Brown Medical School, Providence, RI, USA
Employment & Experience: Since 12/2014: Emmy Noether Research Group Leader, German Research Foundation
07/2011 - 06/2014: Postdoctoral Fellowship, Labor Prof. Filip K. Swirski, Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Since 10/2007: Clinical Fellowship, Heart Center Freiburg, University of Freiburg, Department of Cardiology and Angiology I (Prof. Dr. Christoph Bode)
Scientific Activities: Since 2014: Referee for the Netherlands Organisation for Health Research and Development
(ZonMw) and the British Heart Foundation
Since 2011 Ad hoc Reviewer for ATVB, Circulation, Circulation Research, Hämostaseologie,
Journal of Thrombosis and Thrombolysis, Scientific Reports, PlosOne
11/2009 - 06/2011 Investigator for clinical studies RUBY-1, SAFE-AF, DECREASE
Since 2008 Instructor Seminar in Angiology, ICU Training Electrophysiology, Practical in
Internal Medicine, International Master/PhD Program in Biomedical Sciences

Professional memberships:
Since 2008: American Heart Association, German Cardiac Society, German Atherosclerosis
Society, European Society of Cardiology, Society of Thrombosis and Haemostasis Research


Honors and Awards:

03/2015: W.H. Haus Award, German Atherosclerosis Society

02/2013: Rudolf-Marx Grant, Society of Thrombosis and Haemostasis Research

03/2011: 2-year Research Fellowship, German Research Foundation

01/2005 - 06/2005: German Academic Exchange Service Scholarship for studying at the Brown Medical School, Providence, RI, USA

11/2003 - 11/2005: Research Training Group GK 794 “Cellular mechanisms of immune-associated processes”, University of Tuebingen

09/2003 - 05/2007: German National Academic Foundation


Selected Publications:

Theurl I*, Hilgendorf I*, Nair M*, Tymoszuk P, Haschke D, Aschoff M, He S, Gerhardt LM, Holderried TA, Seifert M, Sopper S, Fenn AM, Anzahl A, Rattik S, McAlpine C, Theurl M, Wieghofer P, Iwamoto Y, Weber GF, Harder N, Chousterman BG, Arvedson TL, McKee M, Wang F, Lutz OM, Rezoagli E, Babies JL, Berra L, Prinz M, Narrendorf M, Weiss G, Weissleder R, Lin HY, Swirski FK. On-demand erythrocyte disposal and iron recycling requires monocyte-derived transient macrophages in the liver. Nat Med. 2016. 22: 945 - 951. (*shared authorship)  Abstract

Lindau A, Härdtner C, Hergeth SP, Blanz KD, Dufner B, Hoppe N, Anto-Michel N, Kornemann J, Zou J, Gerhardt LM, Heidt T, Willecke F, Geis S, Stachon P, Wolf D, Libby P, Swirski FK, Robbins CS, McPheat W, Hawley S, Braddock M, Gilsbach R, Hein L, von zur Mühlen C, Bode C, Zirlik A, Hilgendorf I. Atheroprotection through SYK Inhibition fails in established disease when local macrophage proliferation dominates lesion progression. Basic Res Cardiol. 2016. 111: 20.  Abstract

Ensan S, Li A, Degousee N, Besla R, Cosme J, Roufaiel M, El-Maklizi M, Williams J, Shikatani EA, Li C, Lewis B, Robins L, Yun TJ, Lee JS, Wieghofer P, Khattar R, Byrne J, Ouzounian M, Zavitz CC, Bauer CM, Libby P, Husain M, Swirski FK, Cheong C, Prinz M, Hilgendorf I, Randolph G, Epelman S, Gramolini AO, Cybulsky M, Rubin BB, Levy GA, Farrokhi K, Robbins CS. Self-renewing resident arterial macrophages arise from embryonic CX3CR1+ precursors and circulating monocytes immediately after birth. Nat Immunol. 2016. 17: 159-168.  Abstract

Hilgendorf I, Swirski FK, Robbins CS. Monocyte fate in atherosclerosis. Arterioscler Thromb Vasc Biol. 2015. 35: 272-279. Abstract

Weber GF, Chousterman BG, Hilgendorf I, Robbins CS, Theurl I, Gerhardt LM, Iwamoto Y, Quach TD, Rothstein TL, Nahrendorf M, Weissleder R, Swirski FK. Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis. J Exp Med. 2014. 211: 1243-1256. Abstract

Hilgendorf I, Gerhardt LM, Tan TC, Winter C, Holderried TA, Chousterman BG, Iwamoto Y, Liao R, Zirlik A, Scherer-Crosbie M, Hedrick CC, Libby P, Nahrendorf M, Weissleder R, Swirski FK. Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. Circ Res. 2014; 114: 1611-1622. Abstract

Hilgendorf I, Theurl I, Gerhardt LM, Robbins CS, Weber GF, Gonen A, Iwamoto Y, Degousee N, Holderried TA, Winter C, Zirlik A, Lin HY, Sukhova GK, Butany J, Rubin BB, Witztum JL, Libby P, Nahrendorf M, Weissleder R, Swirski FK. Innate Response Activator B cells aggravate atherosclerosis by stimulating TH1 adaptive immunity. Circulation. 2014; 129: 1677-1687. Abstract

Robbins CS*, Hilgendorf I*, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R, Sukhova GK, Gerhardt LM, Smyth D, Zavitz CC, Shikatani EA, Parsons M, Rooijen NV, Lin HY, Husain M, Libby P, Nahrendorf M, Weissleder R, Swirski FK. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013. 19: 1166 - 1172. (* shared authorship). Abstract

Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, Tiglao E, Figueiredo JL, Iwamoto Y, Theurl I, Gorbatov R, Waring MT, Chicoine AT, Mouded M, Pittet MJ, Nahrendorf M, Weissleder R, Swirski FK. Innate response activator B cells protect against microbial sepsis. Science. 2012. 335: 597-601. Abstract

Hilgendorf I, Eisele S, Remer I, Schmitz J, Zeschky K, Colberg C, Stachon P, Wolf D, Willecke F, Buchner M, Zirlik K, Ortiz-Rodriguez A, Lozhkin A, Hoppe N, von zur Muhlen C, zur Hausen A, Bode C, Zirlik A. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2011. 31: 1991-9. Abstract

Copyright © 2009-2020 University of Freiburg